Biswas Subarna, Hilser James R, Woodward Nicholas C, Wang Zeneng, Gukasyan Janet, Nemet Ina, Schwartzman William S, Huang Pin, Han Yi, Fouladian Zachary, Charugundla Sarada, Spencer Neal J, Pan Calvin, Tang W H Wilson, Lusis Aldons J, Hazen Stanley L, Hartiala Jaana A, Allayee Hooman
Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Nutrients. 2025 Jan 6;17(1):198. doi: 10.3390/nu17010198.
Circulating glycine levels have been associated with reduced risk of coronary artery disease (CAD) in humans but these associations have not been observed in all studies. We evaluated whether the relationship between glycine levels and atherosclerosis was causal using genetic analyses in humans and feeding studies in mice. Serum glycine levels were evaluated for association with risk of CAD in the UK Biobank. Genetic determinants of glycine levels were identified through a genome-wide association study (GWAS) and used to evaluate the causal relationship between glycine and risk of CAD by Mendelian randomization (MR). A dietary supplementation study was carried out with atherosclerosis-prone apolipoprotein E deficient () mice to determine the effects of increased circulating glycine levels on cardiometabolic traits and aortic lesion formation. Among 105,718 UK Biobank subjects, elevated serum glycine levels were associated with significantly reduced risk of prevalent CAD (Quintile 5 vs. Quintile 1 OR = 0.76, 95% CI 0.67-0.87; < 0.0001) and incident CAD (Quintile 5 vs. Quintile 1 HR = 0.70, 95% CI 0.65-0.77; < 0.0001) after adjustment for age, sex, ethnicity, anti-hypertensive and lipid-lowering medications, blood pressure, kidney function, and diabetes. A GWAS meta-analysis with 230,947 subjects identified 61 loci for glycine levels, of which 26 were novel. MR analyses provided modest evidence that genetically elevated glycine levels were causally associated with reduced systolic blood pressure and risk of type 2 diabetes, but did not provide significant evidence for an association with decreased risk of CAD. Glycine supplementation in mice had no effects on cardiometabolic traits or atherosclerotic lesion development. While expanding the genetic architecture of glycine metabolism, MR analyses and in vivo feeding studies did not provide evidence that the clinical association of this amino acid with atherosclerosis represents a causal relationship.
循环中的甘氨酸水平与人类冠状动脉疾病(CAD)风险降低有关,但并非所有研究都观察到了这些关联。我们通过人类基因分析和小鼠喂养研究来评估甘氨酸水平与动脉粥样硬化之间的关系是否具有因果性。在英国生物银行中评估血清甘氨酸水平与CAD风险的关联。通过全基因组关联研究(GWAS)确定甘氨酸水平的遗传决定因素,并用于通过孟德尔随机化(MR)评估甘氨酸与CAD风险之间的因果关系。对易患动脉粥样硬化的载脂蛋白E缺陷()小鼠进行饮食补充研究,以确定循环甘氨酸水平升高对心脏代谢特征和主动脉病变形成的影响。在105718名英国生物银行受试者中,在调整年龄、性别、种族、抗高血压和降脂药物、血压、肾功能和糖尿病后,血清甘氨酸水平升高与显著降低的CAD患病率风险(五分位数5与五分位数1,OR = 0.76,95%CI 0.67 - 0.87;< 0.0001)和CAD发病率风险(五分位数5与五分位数1,HR = 0.70,95%CI 0.65 - 0.77;< 0.0001)相关。一项对230947名受试者的GWAS荟萃分析确定了61个甘氨酸水平的基因座,其中26个是新发现的。MR分析提供了适度的证据,表明遗传上升高的甘氨酸水平与收缩压降低和2型糖尿病风险存在因果关联,但没有提供与CAD风险降低相关的显著证据。给小鼠补充甘氨酸对心脏代谢特征或动脉粥样硬化病变发展没有影响。虽然扩展了甘氨酸代谢的遗传结构,但MR分析和体内喂养研究没有提供证据表明这种氨基酸与动脉粥样硬化的临床关联代表因果关系。